Proteasome inhibition and Tau proteolysis:: an unexpected regulation

被引:46
作者
Delobel, P [1 ]
Leroy, O [1 ]
Hamdane, M [1 ]
Sambo, AV [1 ]
Delacourte, A [1 ]
Buée, L [1 ]
机构
[1] INSERM, Inst Med Predict & Rech Therapeut, U422, F-59045 Lille, France
关键词
Tau protein; proteolysis; phosphorylation; proteasome inhibition;
D O I
10.1016/j.febslet.2004.11.018
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Increasing evidence suggests that an inhibition of the proteasome, as demonstrated in Parkinson's disease, might be involved in Alzheimer's disease. In this disease and other Tauopathies, Tau proteins are hyperphosphorylated and aggregated within degenerating neurons. In this state, Tau is also ubiquitinated, suggesting that the proteasome might be involved in Tau proteolysis. Thus, to investigate if proteasome inhibition leads to accumulation, hyperphosphorylation and aggregation of Tau, we used neuroblastoma cells overexpressing Tau proteins. Surprisingly, we showed that the inhibition of the proteasome led to a bidirectional degradation of Tau. Following this result the cellular mechanisms that may degrade Tau were investigated. (C) 2004 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 28 条
[1]   beta-catenin is a target for the ubiquitin-proteasome pathway [J].
Aberle, H ;
Bauer, A ;
Stappert, J ;
Kispert, A ;
Kemler, R .
EMBO JOURNAL, 1997, 16 (13) :3797-3804
[2]   Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2 [J].
Adamec, E ;
Mohan, P ;
Vonsattel, JP ;
Nixon, RA .
ACTA NEUROPATHOLOGICA, 2002, 104 (01) :92-104
[3]   Tau protein isoforms, phosphorylation and role in neurodegenerative disorders [J].
Buée, L ;
Bussière, T ;
Buée-Scherrer, V ;
Delacourte, A ;
Hof, PR .
BRAIN RESEARCH REVIEWS, 2000, 33 (01) :95-130
[4]   AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer's disease [J].
BueeScherrer, V ;
Condamines, O ;
MourtonGilles, C ;
Jakes, R ;
Goedert, M ;
Pau, B ;
Delacourte, A .
MOLECULAR BRAIN RESEARCH, 1996, 39 (1-2) :79-88
[5]  
Canu N, 1998, J NEUROSCI, V18, P7061
[6]   Proapoptotic effects of Tau cleavage product generated by caspase-3 [J].
Chung, CW ;
Song, YH ;
Kim, IK ;
Yoon, WJ ;
Ryu, BR ;
Jo, DG ;
Woo, HN ;
Kwon, YK ;
Kim, HH ;
Gwag, BJ ;
Mook-Jung, IH ;
Jung, YK .
NEUROBIOLOGY OF DISEASE, 2001, 8 (01) :162-172
[7]   Proteasomal degradation of tau protein [J].
David, DC ;
Layfield, R ;
Serpell, L ;
Narain, Y ;
Goedert, M ;
Spillantini, MG .
JOURNAL OF NEUROCHEMISTRY, 2002, 83 (01) :176-185
[8]   Specificity and mechanism of action of some commonly used protein kinase inhibitors [J].
Davies, SP ;
Reddy, H ;
Caivano, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2000, 351 (351) :95-105
[9]   Stable-tau overexpression in human neuroblastoma cells -: An open door for explaining neuronal death in Tauopathies [J].
Delobel, P ;
Mailliot, C ;
Hamdane, M ;
Sambo, AV ;
Bégard, S ;
Violleau, A ;
Delacourte, A ;
Buée, L .
APOPTOSIS: FROM SIGNALING PATHWAYS TO THERAPEUTIC TOOLS, 2003, 1010 :623-634
[10]   Abnormal Tau phosphorylation of the Alzheimer-type also occurs during mitosis [J].
Delobel, P ;
Flament, S ;
Hamdane, M ;
Mailliot, C ;
Sambo, AV ;
Bégard, S ;
Sergeant, N ;
Delacourte, A ;
Vilain, JP ;
Buée, L .
JOURNAL OF NEUROCHEMISTRY, 2002, 83 (02) :412-420